المؤلفون: Gabriella Liszkay, Catriona McNeil, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Michelle Del Vecchio, Ana Arance, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek

المصدر: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://jitc.bmj.com/content/8/1/e000391.fullTest; https://doaj.org/toc/2051-1426Test

الوصول الحر: https://doaj.org/article/4bc8bf865c8940309a0da0ece09a1891Test

المؤلفون: Fareeda Hosein, Veerle de Pril, Jon M. Richards, Jean-Jacques Grob, Vanna Chiarion-Sileni, Henrik Schmidt, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Alexander M.M. Eggermont, Paolo A. Ascierto, Stefan Suciu, Caroline Robert, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Michele Maio

المساهمون: University of Zurich, Eggermont, Alexander M M

المصدر: Eggermont, A M M, Chiarion-Sileni, V, Grob, J J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbe, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, ' Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma : long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial ', European Journal of Cancer, vol. 119, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.07.001Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, 610 Medicine & health, Ipilimumab, Kaplan-Meier Estimate, Placebo, Adjuvant therapy, Metastasis, Long-term results, Melanoma, Phase III trial, Stage III, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 1306 Cancer Research, Aged, Aged, 80 and over, business.industry, Hazard ratio, 10177 Dermatology Clinic, Cancer, Middle Aged, Prognosis, medicine.disease, Discontinuation, 030104 developmental biology, Chemotherapy, Adjuvant, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business, Follow-Up Studies, medicine.drug

وصف الملف: 806_Eggermont_A._et_al._Adjuvant_ipilimumab_versus_placebo_after_complete_resection_of_stage_III_melanoma_etc._EJC_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211084f57afa1977a4f55abb0eae48ceTest
https://doi.org/10.1016/j.ejca.2019.07.001Test

المؤلفون: Vanna Chiarion-Sileni, Céleste Lebbé, Catriona M. McNeil, Joanna Pikiel, Jean-Jacques Grob, Luc Thomas, Lars Bastholt, Andrzej Mackiewicz, Michele Maio, Omid Hamid, Virginia Ferraresi, Marta Nyakas, Caroline Robert, Michelle Del Vecchio, Burcin Simsek, Michael Smylie, Laurent Mortier, Dirk Schadendorf, Carmen Loquai, Inge Marie Svane, Ana Arance, Gabriella Liszkay, Fareeda Hosein, Piotr Rutkowski, Paolo A. Ascierto, Florent Grange, Christoph Hoeller, Brigitte Dréno, Ralf Gutzmer, Claus Garbe

المساهمون: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy] (INT-FGP), IRCCS Istituto Nazionale dei Tumori [Milano], Poznan University of Medical Sciences [Poland] (PUMS), Institut Gustave Roussy (IGR), Université Paris-Sud - Paris 11 (UP11), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Istituto Oncologico Veneto I.R.C.C.S. [Padova, Italy], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIC Saint Louis (CIC-1427), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Herlev and Gentofte Hospital, Copenhagen University Hospital, Royal Prince Alfred Hospital [Camperdown, Australia] (RPAH), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), University Medical Center [Mainz], Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Claude Huriez [Lille], CHU Lille, Odense University Hospital (OUH), Centre hospitalier universitaire de Nantes (CHU Nantes), University Hospital [Essen, Germany], German Cancer Consortium [Heidelberg] (DKTK), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Oslo University Hospital [Oslo], Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), National Institute of Oncology [Budapest, Hungary], Cross Cancer Institute [Edmonton, AB, Canada], Medizinische Universität Wien = Medical University of Vienna, Regina Elena National Cancer Institute [Rome], Centre Hospitalier Universitaire de Reims (CHU Reims), Medizinische Hochschule Hannover (MHH), Wojewodzkie Centrum Oncologii [Gdańsk, Poland], Bristol-Myers Squibb [Princeton], University Hospital of Siena, Malbec, Odile

المصدر: Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391Test
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391Test
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Immunology, Medizin, Ipilimumab, randomized trials, Gastroenterology, Asymptomatic, law.invention, immunology, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Immunology and Allergy, 030212 general & internal medicine, Adverse effect, RC254-282, Clinical/Translational Cancer Immunotherapy, Pharmacology, business.industry, Incidence (epidemiology), Melanoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, oncology, [SDV] Life Sciences [q-bio], Oncology, 030220 oncology & carcinogenesis, Molecular Medicine, medicine.symptom, business, Brain metastasis, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510133352a63b0beb0ad853bb98c25dbTest
https://www.ncbi.nlm.nih.gov/pubmed/32503946Test

المؤلفون: Rui Wang, Yan Feng, Rebecca A. Moss, Fareeda Hosein, Megan Wind-Rotolo, Jasmine I. Rizzo, Junying Zheng, Xiaozhong Qian, Irene Pak, Akintunde Bello, Abdel Saci, Xiao Shao, Amit Roy

المصدر: Clinical pharmacology and therapeutics. 107(4)

مصطلحات موضوعية: Skin Neoplasms, Metabolic Clearance Rate, medicine.medical_treatment, Machine learning, computer.software_genre, 030226 pharmacology & pharmacy, Proinflammatory cytokine, Machine Learning, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, medicine, Humans, Pharmacology (medical), Model development, In patient, Melanoma, Advanced melanoma, Pharmacology, Chemotherapy, business.industry, Area under the curve, Prognosis, Cytokine, Nivolumab, 030220 oncology & carcinogenesis, Cytokines, Artificial intelligence, business, computer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45cf042d00a0f69475343020bf29510eTest
https://pubmed.ncbi.nlm.nih.gov/31721173Test

المؤلفون: David Smith, Julie R. Brahmer, Michael B. Atkins, F. Stephen Hodi, Jeffrey A. Sosman, David F. McDermott, Joseph F. Grosso, Richard D. Carvajal, Scott J. Antonia, Fareeda Hosein, David R. Spigel, Philip D. Leming, Suzanne L. Topalian, Christopher T. Harbison, Scott N. Gettinger, Alexander Drilon, Mario Sznol, M. Brent McHenry, John D. Powderly, Jedd D. Wolchok

المصدر: JAMA Oncology. 5:1411

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Secondary data, Odds ratio, medicine.disease, Clinical trial, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, Nivolumab, Lung cancer, business, Progressive disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e0fe234acef20bcb507d1a6702c9f2Test
https://doi.org/10.1001/jamaoncol.2019.2187Test

المؤلفون: Abdel Saci, Akintunde Bello, Rui Wang, Megan Wind-Rotolo, Max Qian, Yan Feng, Fareeda Hosein, Jasmine I. Rizzo, Junying Zheng, Xiao Shao, Amit Roy, Rebecca A. Moss, Irene Pak

المصدر: Cancer Research. 79:2273-2273

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Randomization, Receiver operating characteristic, business.industry, medicine.medical_treatment, Melanoma, Dacarbazine, Area under the curve, Cancer, medicine.disease, Machine learning, computer.software_genre, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Cytokine, Oncology, 030220 oncology & carcinogenesis, medicine, Artificial intelligence, Nivolumab, business, computer, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e31eeecc9acb24aaec93fe68e9f6ec7eTest
https://doi.org/10.1158/1538-7445.am2019-2273Test

المؤلفون: Paolo A. Ascierto, Michele Maio, Fareeda Hosein, Jedd D. Wolchok, Virginia Ferraresi, Vanna Chiarion-Sileni, Jeffrey S. Weber, Henrik Schmidt, Alessandro Testori, Omid Hamid, Veerle de Pril, Caroline Robert, Jon M. Richards, Jean-Jacques Grob, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Alexander M.M. Eggermont, Stefan Suciu

المصدر: Journal of Clinical Oncology. 37:2512-2512

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Long term follow up, business.industry, Ipilimumab, Placebo, Complete resection, Surgery, law.invention, Double blind, 03 medical and health sciences, 0302 clinical medicine, Oncology, Randomized controlled trial, law, 030220 oncology & carcinogenesis, medicine, Stage III melanoma, business, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4fe0425f406e2dc849bf0892d7f57916Test
https://doi.org/10.1200/jco.2019.37.15_suppl.2512Test